Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 25Neoplasms 14Colorectal Neoplasms 14Melanoma 12Carcinoma, Renal Cell 11Neoplasm Metastasis 9Solid Tumors 8Carcinoma, Hepatocellular 8Head and Neck Neoplasms 7Urinary Bladder Neoplasms 6Triple Negative Breast Neoplasms 6Stomach Neoplasms 6Squamous Cell Carcinoma of Head and Neck 6Small Cell Lung Carcinoma 6Ovarian Neoplasms 6Lung Neoplasms 6Carcinoma, Transitional Cell 6Breast Neoplasms 6Uterine Cervical Neoplasms 5Lymphoma 5Kidney Neoplasms 4Endometrial Neoplasms 4Solid Tumor 3Pancreatic Neoplasms 3Lymphoma, Non-Hodgkin 3Advanced Solid Tumors 3Urologic Neoplasms 2Treatment-Refractory Solid Tumors 2Solid Cancers 2Recurrence 2

Interventions

atezolizumab 1Etoposide 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × SCLC,Extensive Stage × atezolizumab × Clear all
NCT05595460 2026-04-13

Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC

RayzeBio, Inc.

Phase 1 Active not recruiting
21 enrolled
Thoracic

SCLC,Extensive Stage

Data powered by HemOnc (CC BY 4.0) Colophon âš¡